SKYE Gerald W Mclaughlin buys $0 worth of shares
Jan 04, 2026, 11:43 AM
-14.24%
What does SKYE do
Skye Bioscience, a San Diego-based biopharmaceutical company, focuses on cannabinoid-based therapeutics for metabolic disorders and inflammation. Its Phase 2 candidates include nimacimab for obesity and SBI-100 OE for glaucoma.
Gerald W Mclaughlin bought 12,000 shares of SKYE on 29 May at $0.00 per share, worth a total of $0. They now own 10,000 SKYE shares, or a 600% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.